Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ATG7 | O95352 | 2/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16367338 | 0.86 | ADORA1 (0.43) | L3MBTL1ATG7ADORA1ADORA3ADORA2A | |
| SCHEMBL15183379 | 0.84 | CA1 (0.39) | CA1CA2CA4CA9 | |
| SCHEMBL16367403 | 0.83 | L3MBTL1 (0.38) | L3MBTL1ATG7ADORA1ADORA3ADORA2A | |
| SCHEMBL16367383 | 0.82 | L3MBTL1 (0.39) | L3MBTL1ATG7ADORA1ADORA3ADORA2A | |
| SCHEMBL5911904 | 0.81 | SLC29A1 (0.37) | ADORA3 | |
| SCHEMBL16367335 | 0.80 | ATG7 (0.37) | ATG7ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL15607808 | 0.80 | EGFR (0.42) | ATG7CA1CA2CA9 | |
| SCHEMBL5911972 | 0.79 | ADORA3 (0.41) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL5911964 | 0.79 | ADORA3 (0.41) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL13908945 | 0.78 | RNASE1 (0.32) | ATG7CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | CBR1, CBR3, BLVRB | L3MBTL1 2029/4885ATG7 4374/4885ADORA1 3487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.